Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CASR | P41180 | 2/20 | 0.32 |
| ▸ | ANPEP | P15144 | 3/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3256673 | 1.00 | CYP2D6 (0.43) | CYP2D6CYP2C19CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL8982322 | 1.00 | CYP2D6 (0.43) | CYP2D6CYP2C19CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL23083771 | 0.83 | KDM4E (0.44) | ALDH1A1SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL23083836 | 0.83 | KDM4E (0.44) | ALDH1A1SMN1; SMN2MTNR1AMTNR1B | |
| SCHEMBL28647923 | 0.81 | ANPEP (0.34) | CHRNB2CHRNB4CHRNA4ALDH1A1MTNR1A | |
| SCHEMBL21877077 | 0.80 | CYP2D6 (0.39) | CYP2D6CYP2C19CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL3108858 | 0.77 | — | — | |
| SCHEMBL3121043 | 0.77 | — | — | |
| SCHEMBL2482371 | 0.77 | — | — | |
| SCHEMBL667964 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3310775-B1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | Bayer Pharma AG (DE) | 2020-04-01 | — | — | EP | disclosed |
| US-10227299-B2 | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-12 | — | — | US | disclosed |
| US-20180155285-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-07 | — | — | US | disclosed |
| EP-3310775-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016202755-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | WO | disclosed |
| US-20160297833-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma AG (DE) | 2016-10-13 | — | — | US | disclosed |
| EP-3071577-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015074986-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-05-28 | — | — | WO | disclosed |
| US-8603975-B2 | Cyclic peptide compounds | ASTELLAS PHARMA INC. (JP) | 2013-12-10 | — | — | US | disclosed |
| EP-2150269-B1 | NEW CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2012-11-21 | — | — | EP | disclosed |
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120672-A1 | CYCLIC PEPTIDE COMPOUNDS | VIP, HAVCR2, ZC3HAV1 | CYP2D6 4812/4885CYP2C19 4475/4885CHRNB2 4819/4885 |
| US-20160297833-A1 | THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS | MKNK1, MKNK2, DTYMK | CYP2D6 2118/4885CYP2C19 1622/4885CHRNB2 4772/4885 |
| US-10227299-B2 | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones | MYC, HCCS, MCL1 | CYP2D6 92/4885CYP2C19 329/4885CHRNB2 4643/4885 |
| US-20180155285-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | HCCS, MCL1, MKI67 | CYP2D6 247/4885CYP2C19 895/4885CHRNB2 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.